Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 26, 2007

Allergy Therapeutics Opens Production Plant

  • Allergy Therapeutics opened its new production facility at Worthing, U.K. The new building houses a production line for the company’s Pollinex® Quattro allergy vaccine, which is currently supplied on a named patient basis in Europe.

    The company reports that Pollinex Quattro is also in Phase III development in the first ever Phase III global allergy vaccine trial.

    The new plant has been named The Noon Building while Allergy Therapeutics’ existing building has been renamed The Freeman Building. The namings were in honor of Leonard Noon, M.D., and John Freeman, M.D., who,  while working at St. Mary’s Hospital in London, were the first to use allergy vaccines (published June 1911 in The Lancet).

    In acknowledgment of the pioneering nature of this work Allergy Therapeutics will be making a Research Grant to St. Mary’s Hospital.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »